Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival

被引:2
作者
Chen, Qichen [1 ,3 ]
Li, Kan [2 ,4 ]
Rhodin, Kristen E. [5 ]
Bartholomew, Alex J. [5 ]
Lidsky, Michael E. [5 ]
Wei, Qingyi [3 ,6 ,7 ,8 ]
Cai, Jianqiang [2 ]
Luo, Sheng [9 ]
Zhao, Hong [2 ,10 ]
机构
[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, Dept Colorectal Surg,State Key Lab Oncol South Chi, Guangzhou 510060, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Hepatobiliary Surg,Canc Hosp, Beijing 100021, Peoples R China
[3] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA
[4] Merck & Co Inc, Rahway, NJ USA
[5] Duke Univ, Duke Global Hlth Inst, Duke Sch Med, Dept Surg, Durham, NC 27710 USA
[6] Duke Univ, Duke Global Hlth Inst, Sch Med, Dept Populat Hlth Sci, Durham, NC 27710 USA
[7] Duke Univ, Duke Global Hlth Inst, Sch Med, Dept Med, Durham, NC 27710 USA
[8] Duke Univ, Sch Med, Duke Global Hlth Inst, Durham, NC 27710 USA
[9] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA
[10] Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Hepatobiliary Surg, Beijing, Peoples R China
关键词
SENSITIVITY-ANALYSIS; HEPATIC METASTASES; MANAGEMENT; GUIDELINES; NEOPLASMS;
D O I
10.1016/j.hpb.2023.09.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Despite recommendations for primary tumor resection (PTR) with or without liver resection (LR) in the patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and isolated liver metastases, there are conflicting data for their impact on overall survival (OS).Methods: 2320 patients with GEP-NETs and isolated liver metastases were identified from NCDB. Multiple imputations were used to accommodate missing data, and inverse probability of treatment weighting (IPTW) was conducted to minimize bias.Results: Patients with PTR had a greater OS than those without PTR (3-year rate of 88.6% vs. 69.9%, P < 0.001), which was preserved in the adjusted analysis (IPTW-adjusted HR = 0.387, 95% CI: 0.264-0.567; P < 0.001). Patients with LR had a greater OS than those without LR (3-year rate 87.7% vs. 75.2%, P = 0.003), which was also preserved in adjusted analysis (IPTW-adjusted HR = 0.450, 95% CI: 0.229-0.885; P = 0.021). Patients undergoing both PTR and LR had the greatest survival advantage than those with other surgical interventions (P < 0.001).Conclusions: Either PTR or LR is associated with improved survival for GEP-NET patients with isolated liver metastases. However, there remains significant selection bias in the current study, and caution should be exercised when selecting patients for resection.
引用
收藏
页码:125 / 136
页数:12
相关论文
共 27 条
  • [1] Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS)
    Aoki, Taku
    Kubota, Keiichi
    Kiritani, Sho
    Arita, Junichi
    Morizane, Chigusa
    Masui, Toshihiko
    Kudo, Atsushi
    Komoto, Izumi
    Hatano, Etsuro
    Ito, Tetsuhide
    Osamura, Robert Y.
    Unno, Michiaki
    Uemoto, Shinji
    Kokudo, Norihiro
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2021, 28 (06) : 489 - 497
  • [2] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
    Austin, Peter C.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (25) : 3083 - 3107
  • [3] The National Cancer Data Base: A powerful initiative to improve cancer care in the United States
    Bilimoria, Karl Y.
    Stewart, Andrew K.
    Winchester, David P.
    Ko, Clifford Y.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (03) : 683 - 690
  • [4] Gastroenteropancreatic Neuroendocrine Tumors
    Cives, Mauro
    Strosberg, Jonathan R.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) : 471 - 487
  • [5] Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
    Dasari, Arvind
    Shen, Chan
    Halperin, Daniel
    Zhao, Bo
    Zhou, Shouhao
    Xu, Ying
    Shih, Tina
    Yao, James C.
    [J]. JAMA ONCOLOGY, 2017, 3 (10) : 1335 - 1342
  • [6] Sensitivity Analysis Without Assumptions
    Ding, Peng
    VanderWeele, Tyler J.
    [J]. EPIDEMIOLOGY, 2016, 27 (03) : 368 - 377
  • [7] Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database
    Fairweather, Mark
    Swanson, Richard
    Wang, Jiping
    Brais, Lauren K.
    Dutton, Trevor
    Kulke, Matthew H.
    Clancy, Thomas E.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (08) : 2319 - 2325
  • [8] Recommendations for management of patients with neuroendocrine liver metastases
    Frilling, Andrea
    Modlin, Irvin M.
    Kidd, Mark
    Russell, Christopher
    Breitenstein, Stefan
    Salem, Riad
    Kwekkeboom, Dik
    Lau, Wan-Yee
    Klersy, Catherine
    Vilgrain, Valerie
    Davidson, Brian
    Siegler, Mark
    Caplin, Martyn
    Solcia, Enrico
    Schilsky, Richard
    [J]. LANCET ONCOLOGY, 2014, 15 (01) : E8 - E21
  • [9] The Surgical Management of Small Bowel Neuroendocrine Tumors Consensus Guidelines of the North American Neuroendocrine Tumor Society
    Howe, James R.
    Cardona, Kenneth
    Fraker, Douglas L.
    Kebebew, Electron
    Untch, Brian R.
    Wang, Yi-Zarn
    Law, Calvin H.
    Liu, Eric H.
    Kim, Michelle K.
    Menda, Yusuf
    Morse, Brian G.
    Bergsland, Emily K.
    Strosberg, Jonathan R.
    Nakakura, Eric K.
    Pommier, Rodney F.
    [J]. PANCREAS, 2017, 46 (06) : 715 - 731
  • [10] Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis
    Huettner, Felix J.
    Schneider, Lutz
    Tarantino, Ignazio
    Warschkow, Rene
    Schmied, Bruno M.
    Hackert, Thilo
    Diener, Markus K.
    Buechler, Markus W.
    Ulrich, Alexis
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2015, 400 (06) : 715 - 723